Reducing Adult Inpatients Anxiety With Virtual Reality Meditation: A Prospective, Randomized Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Stanford University
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Hospital Anxiety and Depression Scale (HADS)
Study Overview
Brief Summary
The purpose of the study is to evaluate if non-invasive, distracting devices (virtual reality) can decrease anxiety and improve affect and satisfaction in adult, hospitalized patients.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 99 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •between age 18-99
- •hospitalized at Stanford Health Care
- •english-speaking
Exclusion Criteria
- •significant cognitive impairment or inability to consent
- •current nausea
- •visual problems or currently using corrective glasses that are incompatible with the virtual reality headset
- •a history of severe motion sickness
- •a history of seizures cause by flashing light
- •clinically unstable or require immediate/urgent intervention
Arms & Interventions
Virtual Reality
Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
Intervention: Virtual Reality headset with calming scenery (Behavioral)
Control
No intervention (i.e. virtual reality headset) will be applied to the participant.
Outcomes
Primary Outcomes
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Before and Immediate after intervention
Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.
Secondary Outcomes
No secondary outcomes reported
Investigators
Thomas Caruso
Clinical Professor
Stanford University